Next, we similarly evaluated sitagliptin (Januvia®), which is a selective inhibitor of dipeptidyl peptidase 4 (DPP-4), and is used as monotherapy or in association with other anti-diabetic drugs (i.e. metformin) in the treatment of T2D. Here, DPP4 is linked to type 2 diabetes mellitus.